SCHEMBL21122002

SCHEMBL21122002

Nc1ccc(-n2cc(-c3cccc(-c4cn(-c5ccc(N)cc5)nn4)c3)nn2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 2/20 0.63
HSD17B2 P37059 2/20 0.63
HDAC3 O15379 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
CA1 P00915 3/20 0.56
CA2 P00918 3/20 0.56
CA5A P35218 3/20 0.56
CA5B Q9Y2D0 3/20 0.56
CA12 O43570 2/20 0.52
CA9 Q16790 2/20 0.52
PTGS2 P35354 2/20 0.52
KEAP1 Q14145 2/20 0.52
NFE2L2 Q16236 2/20 0.52
MAPT P10636 1/20 0.50
SNCA P37840 1/20 0.50
MIF P14174 1/20 0.49
PTGS1 P23219 1/20 0.49
TERT O14746 2/20 0.47
STIM1 Q13586 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758635 0.88 CA2 (0.66) HSD17B1HSD17B2HDAC3HDAC1HDAC6
SCHEMBL21159739 0.81 MIF (0.49) HSD17B1HSD17B2HDAC3HDAC1HDAC6
SCHEMBL11904306 0.81 CA1 (0.57) HSD17B1HSD17B2HDAC3HDAC1HDAC6
SCHEMBL31530343 0.81 CA1 (0.51) HSD17B1HSD17B2HDAC3HDAC1HDAC6
SCHEMBL22833938 0.80 CYP1B1 (0.63) HSD17B1HSD17B2CA1CA2CA5A
SCHEMBL21160019 0.79 CDC7 (0.48) HSD17B1HSD17B2HDAC3HDAC1HDAC6
SCHEMBL29531292 0.79 CDC7 (0.48) HSD17B1HSD17B2HDAC3HDAC1HDAC6
SCHEMBL28949786 0.79 HSD17B1 (0.61) HSD17B1HSD17B2CA1CA2CA5A
SCHEMBL21122080 0.78 STIM1 (0.65) HSD17B1HSD17B2CA1CA2CA5A
SCHEMBL17002341 0.78 KEAP1 (0.58) HSD17B1HSD17B2HDAC3HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250075265-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS ROCHE SEQUENCING SOLUTIONS INC (US) 2025-03-06 US claimed
US-11970731-B2 Enhancement of nucleic acid polymerization by aromatic compounds Roche Sequencing Solutions, Inc. (US) 2024-04-30 US claimed
EP-3735409-B1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS INC (US) 2023-06-21 EP claimed
EP-3994262-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Stratos Genomics Inc. (US) 2022-05-11 EP claimed
US-20220112548-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. 2022-04-14 US claimed
US-20210062251-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. 2021-03-04 US claimed
WO-2020263703-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS, INC. (US) 2020-12-30 WO claimed
EP-3735409-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Stratos Genomics Inc. (US) 2020-11-11 EP claimed
WO-2019135975-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS INC. (US) 2019-07-11 WO claimed
US-20250075265-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS ROCHE SEQUENCING SOLUTIONS INC (US) 2025-03-06 US disclosed
US-11970731-B2 Enhancement of nucleic acid polymerization by aromatic compounds Roche Sequencing Solutions, Inc. (US) 2024-04-30 US disclosed
EP-3735409-B1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS INC (US) 2023-06-21 EP disclosed
EP-3994262-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Stratos Genomics Inc. (US) 2022-05-11 EP disclosed
US-20220112548-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. 2022-04-14 US disclosed
US-20210062251-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS Roche Sequencing Solutions, Inc. 2021-03-04 US disclosed
WO-2020263703-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS, INC. (US) 2020-12-30 WO disclosed
WO-2020263703-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS, INC. (US) 2020-12-30 WO disclosed
WO-2019135975-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS INC. (US) 2019-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210062251-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS POLN, POLB, POLRMT HSD17B1 3522/4885HSD17B2 3960/4885HDAC3 4794/4885
US-11970731-B2 Enhancement of nucleic acid polymerization by aromatic compounds POLN, POLB, POLRMT HSD17B1 3522/4885HSD17B2 3960/4885HDAC3 4794/4885
US-20250075265-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS POLN, POLB, POLRMT HSD17B1 3522/4885HSD17B2 3960/4885HDAC3 4794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.